RT Journal Article
SR Electronic
A1 Vinall, Phil
T1 Non-Vertebral Fracture Reduction with High- vs Low-Dose Ibandronate
JF MD Conference Express
YR 2007
FD SAGE Publications
VO 7
IS 4
SP 16
OP 16
DO 10.1177/155989770700700412
UL http://mdc.sagepub.com/content/7/4/16.abstract
AB Results from the Oral IBandronate Osteoporosis Vertebral Fracture Trial in North America and Europe [BONE] study showed a significant (p=0.0001) 62% reduction in the risk of vertebral fractures in women with postmenopausal osteoporosis treated with oral ibandronate, either as 2.5 mg daily or as 20 mg every other day for 12 doses every 3 months [Chesnut CH et al. Bone Miner Res 2004].